Literature DB >> 30459136

A case of entecavir-associated bullous fixed drug eruption and a review of literature.

Selami Aykut Temiz1, İlkay Özer1, Arzu Ataseven1, Sıddıka Fındık2.   

Abstract

Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the same site(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC) is considered to play a role in FDE etiology. Several antibiotics, barbiturates, oral contraceptives, nonsteroidal anti-inflammatory drugs, laxative-containing phenolphthalein, metronidazole, and quinine are known to be the primary drugs responsible for FDE. Bullous FDE, on the other hand, is a relatively rare form of FDE. Hepatitis B is a significant worldwide health problem, and entecavir is a common nucleoside (deoxyguanosine) analog used for treating hepatitis B; however, it has various side effects, such as lactic acidosis, myalgia, azotemia, hypophosphatemia, headache, diarrhea, pancreatitis, and neuropathy, and, in rare cases, cutaneous drug eruption. Our aim is to present a case of entecavir-associated bullous drug reaction, which has not been reported in the literature. Furthermore, we performed a review of literature to compile previously reported entecavir-associated drug reactions.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30459136      PMCID: PMC6428509          DOI: 10.5152/tjg.2018.17887

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  18 in total

Review 1.  Fixed drug eruptions: presentation, diagnosis, and management.

Authors:  Hal Flowers; Robert Brodell; Melissa Brents; Julie Porter Wyatt
Journal:  South Med J       Date:  2014-11       Impact factor: 0.954

Review 2.  Fixed drug eruption: state of the art.

Authors:  Esen Ozkaya
Journal:  J Dtsch Dermatol Ges       Date:  2007-12-10       Impact factor: 5.584

3.  The use of skin testing in the investigation of cutaneous adverse drug reactions.

Authors:  A Barbaud; S Reichert-Penetrat; P Tréchot; M A Jacquin-Petit; A Ehlinger; V Noirez; G C Faure; J L Schmutz; M C Béné
Journal:  Br J Dermatol       Date:  1998-07       Impact factor: 9.302

4.  Maculopapular-type drug eruption caused by entecavir.

Authors:  Shigenori Yamada; Yu Sawada; Motonobu Nakamura
Journal:  Eur J Dermatol       Date:  2011 Jul-Aug       Impact factor: 3.328

5.  Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis.

Authors:  Alfredo Marzano; Andrea Marengo; Milena Marietti; Mario Rizzetto
Journal:  Dig Liver Dis       Date:  2011-07-22       Impact factor: 4.088

Review 6.  Adverse cutaneous reactions to mood stabilizers.

Authors:  Julia K Warnock; David W Morris
Journal:  Am J Clin Dermatol       Date:  2003       Impact factor: 7.403

7.  Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B.

Authors:  Jeong Tae Kim; Hye Won Jeong; Ki Hwa Choi; Tae Young Yoon; Nohyun Sung; Young Ki Choi; Eun Ha Kim; Hee Bok Chae
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

8.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

Review 9.  Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management.

Authors:  A Neil Crowson; Tricia J Brown; Cynthia M Magro
Journal:  Am J Clin Dermatol       Date:  2003       Impact factor: 7.403

Review 10.  Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.

Authors:  Anastasia Rivkin
Journal:  Drugs Today (Barc)       Date:  2007-04       Impact factor: 2.245

View more
  2 in total

1.  "Black box warning" rash with entecavir - case report.

Authors:  Xiong Khee Cheong; Zhiqin Wong; Norazirah Md Nor; Bang Rom Lee
Journal:  BMC Gastroenterol       Date:  2020-09-18       Impact factor: 3.067

2.  Hypopigmented penile fixed drug eruption.

Authors:  Perpetua U Ibekwe; Hafees O Ajibola; Zainabb Babba; Grace Otokpa; Raphael Solomon; Bob A Ukonu
Journal:  Clin Case Rep       Date:  2022-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.